Related by context. All words. (Click for frequent words.) 80 ADHD Rating Scale 71 Montgomery Asberg Depression 70 Rating Scale MADRS 70 YMRS 69 ADAS cog 69 Negative Syndrome 69 IBDQ 69 PANSS 67 MADRS 67 UPDRS 67 Unified Parkinson Disease 66 depressive symptom 66 MMSE score 66 Montgomery Åsberg Depression 66 symptom severity 66 ADAS Cog 66 Alzheimer Disease Assessment 66 Y BOCS 66 IRLS score 66 Crohn Disease Activity 65 MADRS score 65 baseline PASI 65 Brief Psychiatric 65 HDRS 65 Scale PANSS 65 nasal symptom 65 PANSS total 65 NIH CPSI 65 Global Impression CGI 64 ADCS CGIC 64 Index CDAI 64 UPDRS II 64 CNS LS 64 TNSS 64 Score DAS# 63 BMI z 63 Global Impression 63 HAM D# 63 UPDRS motor 62 HAQ DI 62 State Examination MMSE 62 mg BID dose 62 APACHE II 62 PREZISTA r arm 62 Rating Scale UPDRS 61 Psoriasis Area 61 Scale EDSS 61 IRLS 61 Expanded Disability Status 61 HAM D 61 PASI scores 61 SSRI SNRI 61 baseline HbA1c 61 Scale cognitive subscale 60 liver histology 60 ADCS ADL 60 NIHSS 60 Negative Symptoms 60 MoxDuo TM IR 60 subscores 60 Hamilton Rating Scale 60 subscale scores 60 lumbar spine BMD 60 CDAI score 60 MMSE 60 hemoglobin A1c HbA1c 60 QIDS SR 60 quetiapine XR 60 HOMA IR 60 PANSS scores 60 EDSS score 60 DLQI 59 PERMP 59 insulin detemir 59 AUA Symptom Score 59 internalizing behaviors 59 Index CDAI score 59 WOMAC pain 59 BPH Symptom Score 59 HbA 1c levels 59 tapentadol ER 59 severe exacerbations 59 REYATAZ r arm 59 NYHA functional class 59 Severity Index PASI 59 NPH insulin 59 secondary efficacy endpoint 58 symptomatic VTE 58 ziprasidone 58 HAMD 58 HbA1c levels 58 divalproex sodium 58 GERD symptom 58 Hb A1C 58 glycated hemoglobin 58 baseline FEV 58 adjunctive placebo 58 Scale EDSS score 58 serum IGF 58 International Prostate Symptom 58 HRQL 58 clinically meaningful improvement 58 SGRQ 58 CDAI 58 Secondary efficacy endpoints 58 preoperative PSA 58 rhinoconjunctivitis 58 -#.# mg dL [002] 58 subscore 57 rosuvastatin #mg 57 baseline A1C 57 posttest 57 oxycodone CR 57 apnea hypopnea index 57 serum urate 57 HBeAg negative patients 57 p = .# [002] 57 Mania Rating Scale 57 HbA 1c 57 serum phosphorous 57 IPSS 57 Rating Scale 57 quetiapine 57 glycated hemoglobin HbA1c 57 interrater reliability 57 DAS# scores 57 HADS 57 hemoglobin A1c levels 57 lopinavir r arm 57 serum sodium 57 % Confidence Interval 57 virologic response 57 mg kg dose 57 adjunctive ABILIFY 57 Rating Scale BPRS 57 Primary endpoints 57 serum potassium 57 #q# deletion syndrome 57 EDSS scores 57 Score IPSS 57 undetectable HBV DNA 57 CANCIDAS 57 extrapyramidal symptoms 57 hsCRP levels 57 virological response 57 Secondary endpoints 57 MMSE scores 57 #mg BID [003] 57 aripiprazole 57 Epworth Sleepiness Scale 57 venlafaxine XR 57 achieved statistical significance 57 ANCOVA 57 prespecified secondary 57 fasting plasma glucose 57 RLAI 57 Visual Analog Scale 56 Glasgow Coma Scale 56 tipranavir r 56 plasma HCV RNA 56 serum phosphorus 56 risperidone 56 WOMAC TM 56 Depression Inventory 56 mRS 56 Inventory BPI 56 atorvastatin #mg 56 subscales 56 confirmed CCyR 56 ETDRS 56 CR nPR 56 asthma exacerbations 56 eplerenone 56 urinary N telopeptide 56 receiving golimumab 56 Neuropsychiatric Inventory 56 corticosteroid dose 56 -#.# log# copies mL 56 glycosylated hemoglobin HbA1c 56 mTSS 56 #mg/day [001] 56 secondary efficacy endpoints 56 HbA1C levels 56 CCyR 56 annualized relapse 56 achieving PASI 56 antipsychotic efficacy 56 BMI percentiles 56 Knodell necroinflammatory score 56 prespecified 56 fasting plasma glucose FPG 56 desvenlafaxine succinate 56 receiving Vectibix monotherapy 56 Depression Rating Scale 56 Pain Intensity 56 mcg QD 56 concomitant medications 56 adenoma recurrence 56 composite endpoint 56 Ishak fibrosis score 56 Acute Physiology 56 elevated ALT 56 serum HBV DNA 56 emotional lability 56 Pain Rating Scale 56 Severity MSCS score 56 hsCRP 56 citalopram 56 attain statistical significance 56 ACR Pedi 56 sd = 56 BPRS 56 SELENA SLEDAI score 56 CONCERTA ® 55 solifenacin 55 PSQI 55 HAM D# scores 55 NATRECOR R 55 intima media thickness 55 Secondary endpoints included 55 mg/m2 dose 55 inattention hyperactivity 55 CI -#.# 55 serum creatinine levels 55 Fibromyalgia Impact Questionnaire 55 aldosterone antagonist 55 Hemoglobin A1c 55 CIBIC plus 55 Treatment Diabetic Retinopathy 55 #mg q8h 55 Visual Analogue Scale VAS 55 fasting insulin 55 mg RDEA# 55 linaclotide treated 55 State Exam MMSE 55 Pred Forte 55 hyperactive impulsive 55 ACR# ACR# 55 neutrophil counts 55 Wechsler Intelligence 55 NCQA accreditation surveys 55 hyperactivity impulsivity 55 PSADT 55 EQ 5D 55 HBV DNA levels 55 apolipoprotein B 55 blood Phe levels 55 platelet reactivity 55 certolizumab 55 calculated creatinine clearance 55 QTc 55 moderate renal impairment 55 TEAEs 55 HbA 1C 55 oxcarbazepine 55 Non inferiority 55 #.#/#.# mmHg [001] 55 5-FU/LV 55 DAS# [002] 55 nonfatal MI 55 dosing cohort 55 evaluable subjects 55 postintervention 55 lopinavir r 55 glycated hemoglobin levels 55 nighttime awakenings 55 ANOVA 55 splenectomized patients 55 ALT elevations 55 morphometric vertebral fractures 55 rimonabant #mg 55 tiotropium 55 montelukast 55 Clinician Administered PTSD 55 Kaplan Meier analysis 55 Ocular Surface Disease 55 irbesartan 55 serum cortisol 55 retinal thickness 55 #.#mg/dL 55 log# copies mL 55 CORE OM 55 divalproex 55 angiographic outcomes 55 tolvaptan 55 ARB telmisartan 55 A1c levels 55 mcg linaclotide 54 euthymic patients 54 IIEF 54 Secondary endpoints include 54 Likert pain 54 CHADS2 54 Bayley Scales 54 p = .# [001] 54 LVEF 54 endoscopic remission 54 Cmax 54 posttreatment 54 dose Iluvien 54 elevated creatinine 54 SKAMP D 54 periprocedural 54 LEXIVA 54 non menstrual pelvic 54 relapsed MM 54 Global Impression Severity 54 MAS XR 54 SUVmax 54 exploratory endpoints 54 Scale Cognitive Subscale 54 AUA BPH Symptom Score 54 Operative mortality 54 lamotrigine 54 CPAP adherence 54 sUA 54 treat NNT 54 -#.# log# 54 recurrent venous thromboembolism 54 Health Assessment Questionnaire 54 atheroma volume 54 serum phosphate levels 54 mmol l 54 serum testosterone 54 psychosocial functioning 54 insulin glargine 54 levetiracetam 54 systolic BP 54 QTcF 54 symptom exacerbation 54 Functioning GAF 54 ADHD symptoms 54 Interrater reliability 54 viral kinetics 54 ACTEMRA TM 54 mean baseline HbA1c 54 receiving VICTRELIS 54 seroprotection 54 #mg/day [002] 54 serum leptin 54 VFQ 54 mean baseline A1C 54 NIHSS score 54 REYATAZ ritonavir 54 Symptom Score 54 Brief Pain 54 incontinence episodes 54 LS BMD 54 conditional logistic regression 54 somatic symptom 54 mcg albinterferon alfa 2b 54 pramipexole 54 Mean Symptom Complex 54 pegylated interferon alfa 2b 54 INVEGA ® 54 DAS# CRP 54 serum calcium 54 nondepressed 54 dysthymia 54 mg BID 54 dexmedetomidine 54 statistical significance p 54 sustained virological response 54 hypoglycemic events 54 HRQOL 54 conventional antipsychotics 54 glycosylated hemoglobin 54 carotid IMT 54 rt PA 54 placebo fluoxetine 54 binary restenosis 54 aspartate aminotransferase 54 prospectively defined 54 mg Proellex 54 cerebrovascular events 54 placebo p 54 HBeAg seroconversion 54 nocturnal hypoglycemia 54 PANSS Positive 54 Visual acuity 54 FOLFOX4 54 IELT 54 salivary cortisol 54 point Likert scale 54 x ULN 54 LEXIVA r 54 neuroleptic 54 clinically meaningful 54 UPDRS scores 54 histological subtype 54 virologic failure 54 WOMAC 54 biopsy Gleason 54 STRIDE PD 54 dapagliflozin plus 54 â ‰ ¥ 54 #μg [001] 53 Status Scale EDSS 53 femoral neck BMD 53 unpaired t 53 achieved ACR# 53 dose atorvastatin 53 NHANES III 53 EURIDIS 53 Subgroup analysis 53 EDSS 53 mcg BID 53 ATACAND 53 Abnormal Involuntary Movement 53 BENICAR HCT 53 neurocognitive function 53 #mg dose [003] 53 HER2 expression 53 hemoglobin A1C 53 DAS# remission 53 Physical Component 53 angiotensin converting enzyme inhibitors 53 HRQoL 53 Neuropsychiatric Inventory NPI 53 HbA1C 53 risperidone Risperdal 53 fructosamine 53 abacavir lamivudine 53 fasting glucose levels 53 subtest 53 estimated GFR 53 Mental Component 53 depressive symptomatology 53 D dimer 53 rotigotine 53 tocilizumab 53 valproate 53 sustained virologic response 53 intraobserver 53 -#.# ± [002] 53 serum CRP 53 plasma leptin 53 UACR 53 lymphocyte count 53 Pharmacokinetic parameters 53 syndromal 53 highest tertile 53 System IPSS 53 aminotransferase levels 53 cytogenetic response 53 interobserver reliability 53 subsyndromal 53 depressive symptoms 53 salmeterol fluticasone 53 teriflunomide 53 oral prednisolone 53 racemic albuterol 53 plasma folate 53 Wechsler Memory 53 p = #.# [003] 53 glycosylated hemoglobin levels 53 safinamide 53 methotrexate monotherapy 53 antihypertensive medications 53 demonstrated statistically significant 53 alanine aminotransferase 53 Disease Activity 53 logistic regression model 53 specific antigen PSA 53 quetiapine risperidone 53 NIS LL 53 hippocampal volume 53 unfractionated heparin 53 Visual Analog 53 Thrombolysis 53 ACR# response 53 vaginal progesterone gel 53 MIRAPEX ER 53 lispro 53 guanfacine extended release 53 hip BMD 53 % CI #.#-#.# [007] 53 ULORIC 53 subanalysis 53 ritonavir boosted 53 DLTs 53 adenotonsillectomy 53 TIMI 53 neostigmine 53 multivariate Cox 53 serum aminotransferase levels 53 primary hypercholesterolemia 53 nondiabetic patients 53 fosamprenavir 53 mg Pycnogenol 53 ng dL 53 Symptom Checklist 53 aspartate aminotransferase AST 53 definite stent thrombosis 53 SSRI citalopram 53 Symptom severity 53 recurrent VTE 53 Lupuzor ™ 53 psychiatric comorbidities 53 pCR 53 abatacept 53 sUA levels 53 mg XP# 53 FOLPI 53 laboratory abnormalities 53 Depressive symptoms 53 virologic 52 Mini Mental 52 TMC# r 52 FEV1 52 variance ANOVA 52 elevated serum creatinine 52 postprocedure 52 ARICEPT 52 active comparator 52 CRp 52 symptomatology 52 subjective sleepiness 52 XIENCE V PROMUS Stent 52 omalizumab 52 hypoglycemic episodes 52 death reinfarction 52 GH deficiency 52 serum uric acid 52 blinded randomized placebo controlled 52 postdose 52 umol L 52 preoperatively 52 hematologic parameters 52 allele frequencies 52 elevated LDH 52 exhaled nitric oxide 52 metabolic parameters 52 APTIVUS r 52 alanine aminotransferase ALT 52 Scale CNS 52 scores TNSS 52 HbA1c 52 Baseline characteristics 52 HIV HCV coinfected 52 Hemoglobin A1c HbA1c 52 Ashworth Scale 52 Depressive Symptoms 52 XIENCE V demonstrated 52 tirofiban 52 chlorambucil 52 μg dose 52 confidence intervals CIs 52 biochemical recurrence 52 paliperidone ER 52 coronary stenosis 52 diuretic chlorthalidone 52 lowest tertile 52 pharmacodynamic 52 % CI #.#-#.# [004] 52 mL/min/#.# m 2 52 aminotransferases 52 Child Behavior Checklist 52 typical antipsychotics 52 clozapine 52 overnight polysomnography 52 convergent validity 52 sweat chloride 52 Timed Walk 52 bivalirudin monotherapy 52 plus dexamethasone 52 opioid naïve 52 sertraline 52 donepezil 52 tertile 52 mcg doses 52 SCr 52 hemoglobin concentration 52 ALT flares 52 tapentadol IR 52 Main Outcome Measures 52 BYSTOLIC 52 fasting glucose 52 subtests 52 COPD exacerbation 52 clomipramine 52 perioperative mortality 52 mg ustekinumab 52 placebo p = 52 clinically meaningful improvements 52 meta regression 52 daytime sleepiness 52 pain subscale 52 methacholine challenge 52 T2DM 52 lipid parameters 52 systemic corticosteroid 52 antibody titers 52 univariate analyzes 52 estimated glomerular filtration 52 colesevelam HCl 52 total cholesterol LDL 52 leukocyte count 52 ± SD 52 HSCT 52 Wechsler Adult 52 reactogenicity 52 baseline FEV1 52 complete cytogenetic response 52 MACCE 52 aPTT 52 Personality disorders 52 covariate 52 hyperphenylalaninemia HPA due 52 Pegasys ® 52 ng dl 52 azacitidine 52 #.#/#.# mm Hg [003] 52 lymphopenia 52 mean ± SEM 52 inflammatory lesions 52 eszopiclone 52 biochemical relapse 52 SCIg 52 meta analytic 52 KCCQ 52 analgesic efficacy 52 nmol L. 52 preintervention 52 Dyspnea 52 antiretroviral naive 52 Edinburgh Postnatal Depression 52 alteplase 52 BLLs 52 d dimer 52 arterial thromboembolic events 52 serum concentrations 52 tertiles 52 mg QD 52 UPDRS Part III 52 Flu Cy 52 erection hardness 52 Platelet counts 52 QoL 52 clodronate 52 RECIST Response Evaluation Criteria 52 3mg/kg 52 #.#ng/ml 52 haematologic 52 ± SEM 52 ALT elevation 52 serum estradiol 52 noninferiority 52 highly emetogenic 52 ertapenem 52 RLS symptoms 52 dose proportionality 52 hypomanic symptoms 52 RESIST studies 52 Key secondary endpoints 52 pulmonary exacerbations 52 adalimumab 52 bivariate analyzes 52 nonpsychotic 52 chlorthalidone 52 postoperative mortality 52 serum phosphate 52 CrCl 52 PEGINTRON TM 52 SDAA II 52 timepoint 52 elevated troponin 51 HBeAg negative chronic hepatitis 51 nadroparin 51 mEq L 51 dose cohorts 51 NATRECOR ® 51 p = NS 51 multivariable analysis 51 micafungin 51 statistically significant p 51 QTc intervals 51 Distress Scale 51 #OHD 51 microg 51 atazanavir ritonavir 51 COPD exacerbations 51 bepotastine besilate nasal spray 51 neurodevelopmental impairment 51 hepatic enzyme 51 bosentan 51 mm Hg systolic 51 urinary cortisol 51 refractory ischemia 51 fluoxetine paroxetine 51 REMINYL ® 51 OGTT 51 nicardipine 51 antiepileptics 51 FDA defined valvulopathy 51 serum BDNF 51 mucosal healing 51 antibody titer 51 airway responsiveness 51 ONGLYZA saxagliptin 51 generalized anxiety disorder GAD 51 bronchial hyperresponsiveness 51 inhibin 51 discontinuations due 51 underwent CABG 51 plus methotrexate 51 Apgar scores 51 = #.#-#.# 51 FACIT Fatigue 51 nonsignificant trend 51 Wilcoxon rank sum 51 serum urate levels 51 ascending dose 51 multivariate analyzes 51 MADRS scores 51 creatinine levels 51 transaminase elevations 51 CR CRu 51 Solid Tumors 51 mg dose 51 retest reliability 51 plasma cortisol 51 pharmacokinetics PK 51 pretreatment baseline 51 neutropaenia 51 pentoxifylline 51 hematologic toxicities 51 AGILECT ® 51 urine albumin 51 suicide attempters 51 glomerular filtration rate 51 sertraline Zoloft 51 VaD 51 serum calcium levels 51 EBMT criteria 51 Recurrence Score 51 olanzapine quetiapine 51 Perceived Stress Scale 51 apnea hypopnea 51 cilostazol 51 6MWD 51 odds ratios ORs 51 albumin excretion 51 Cronbach alpha 51 A1C levels 51 oral anticoagulation 51 ABC/3TC 51 mcg kg 51 RE LY 51 pulmonary capillary wedge 51 efavirenz EFV 51 pyridostigmine 51 avosentan 51 interpersonal psychotherapy 51 landmark ATHENA 51 expiratory flow 51 nmol l 51 lymphocytosis 51 reinfarction 51 paricalcitol 51 Ejection Fraction 51 β blocker 51 BPH symptom 51 Fasting plasma glucose 51 dosing cohorts 51 creatinine clearance 51 Total Nasal Symptom 51 Adult ADHD 51 Depression Inventory BDI 51 Pharmacokinetic 51 events SAEs 51 BENICAR 51 sensitivity specificity 51 attention-deficit/hyperactivity disorder ADHD 51 μmol L 51 pharmacodynamic PD 51 inflammatory biomarkers 51 pharmacodynamics PD 51 clinically meaningful reductions 51 Likert 51 somatic symptoms 51 dose clopidogrel 51 PREZISTA r 51 μg kg 51 risperidone olanzapine 51 Likert type 51 Major Depressive Disorder 51 serologically active patients 51 dasatinib 51 cells uL 51 Prehypertension 51 gout flares 51 hemoglobin concentrations 51 HBeAg 51 ramelteon 51 akathisia 51 actigraphy 51 genotypic resistance 51 rhIGF 51 Kaplan Meier estimates 51 prognostic variables 51 peginterferon alfa 2a 51 WAIS III 51 Commended Performance 51 stage IIIb 51 concomitant AEDs 51 serum PSA 51 Univariate 51 ASIA Impairment 51 postop 51 patients evaluable 51 lactate dehydrogenase LDH 51 seroconverted 51 VKORC1 51 OADs 51 dactylitis 51 viral kinetic 51 lacosamide 51 cardiac autonomic 51 diastolic blood pressures 51 visilizumab 51 primary generalized tonic 51 Economically disadvantaged students 51 plasma glucose 51 neuroleptics 51 clinicopathological features 51 interobserver 51 transaminase levels 51 surrogate endpoint 51 etanercept 50 ACCORD Lipid 50 lymphocyte counts 50 multivariable Cox 50 IOP lowering 50 mm Hg diastolic 50 univariate 50 prospectively stratified 50 somatostatin analog 50 subthreshold depression 50 dacarbazine chemotherapy 50 virologic responses 50 permanently discontinue Vectibix 50 oral diclofenac 50 venlafaxine Effexor 50 tumor progression TTP 50 fluoxetine Prozac 50 timepoints 50 HBeAg positive 50 probands 50 CIMZIA ™ 50 uncorrected visual acuity 50 MS DRGs 50 plasma pharmacokinetics 50 neurocognitive functioning 50 nonadherence 50 pretest probability 50 rectal bleeding subscore 50 antipsychotic 50 serum folate concentrations 50 leucopenia 50 primary efficacy endpoint 50 quetiapine Seroquel 50 psychiatric comorbidity 50 Ziprasidone 50 creatinine clearance CrCl 50 affective psychosis 50 Subscale 50 ezetimibe simvastatin 50 postoperative AF 50 QTc prolongation 50 NWEA MAP 50 Available Seat Kilometres ASKs 50 atypical antipsychotic medications 50 CSBMs 50 #.#mmol L [001] 50 PSA nadir 50 partial onset seizures 50 demonstrated clinically meaningful 50 Likert Scale 50 follicular NHL 50 doxorubicin docetaxel 50 mmol L. 50 unipolar depression 50 MCyR 50 DSM IV diagnosis 50 attention-deficit/hyperactivity disorder 50 fondaparinux 50 dose cohort 50 achieved sustained virological 50 haloperidol Haldol 50 coinfected 50 carotid intima media 50 Descriptive statistics 50 placebo dexamethasone 50 logistic regression analysis 50 HF hospitalization 50 postoperative delirium 50 asthma exacerbation 50 mirtazapine 50 CD4 + cell 50 Logistic regression 50 Bonferroni correction 50 hypoglycaemic episodes 50 low dose cytarabine 50 ACR# responses 50 median CD4 50 pharmacodynamic effects 50 PRADAXA #mg 50 Multicenter Automatic Defibrillator Implantation 50 prepubertal 50 HOMA scores 50 myocardial blush 50 PreCISe study 50 sham injections 50 Pearson correlation coefficient 50 darunavir ritonavir 50 serum folate 50 KOOS 50 postoperative complication 50 insulin degludec 50 mL sec 50 μg dL 50 SELENA SLEDAI 50 fasting blood glucose 50 correlation coefficients 50 statistically significant improvement 50 Symbyax 50 macrovascular events 50 Erectile Function IIEF 50 prolactin levels 50 μg d 50 residual platelet reactivity 50 leukopenia 50 remission CR 50 mITT population 50 atherothrombotic events 50 TAXUS Express Stent 50 serum magnesium 50 internalizing disorders 50 clozapine Clozaril 50 per deciliter mg 50 diastolic pressure 50 corrected QT interval 50 Poisson regression 50 Viral load 50 P = .# 50 Stroke Scale 50 placebo controlled Phase 50 serum triglycerides 50 nonsignificant 50 polysomnographic 50 STN stimulation 50 ACCOMPLISH 50 invasive aspergillosis 50 paliperidone palmitate 50 prospective multicentre 50 anemia hemoglobin 50 nmol L 50 dyspnea 50 lanthanum carbonate 50 olanzapine 50 Advanced Proficient 50 CFQ R 50 statistically nonsignificant 50 imatinib therapy 50 -#.# mg dL [001] 50 ALS Functional 50 Endocrine Therapy 50 AST ALT 50 nonfatal myocardial infarction MI 50 FOSRENOL ® 50 DAPT 50 events AEs 50 mITT 50 donepezil Aricept 50 oxygen desaturation 50 IFN alfa 50 PLMS 50 macroalbuminuria 50 nucleoside naive 50 ug dose 50 NYHA 50 peginterferon alfa 2b 50 angiographic restenosis 50 paresthesias 50 PDSS 50 atrioventricular block 50 % CI #.#-#.# [003] 50 Kruskal Wallis test 50 Numeric Rating Scale 50 asymptomatic carotid stenosis 50 infarct size 50 HIV RNA 50 fasting plasma 50 hs CRP 50 AGILECT R 50 ziprasidone Geodon 50 dyslipidaemia 50 Arch Intern Med